Citadel Advisors’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $16.7M | Sell |
50,600
-7,100
| -12% | -$2.42M | ﹤0.01% | 2551 |
|
|
2025
Q4 | $22.9M | Buy |
57,700
+9,300
| +19% | +$4.12M | ﹤0.01% | 2185 |
|
|
2025
Q3 | $22.1M | Sell |
48,400
-11,900
| -20% | -$4.85M | ﹤0.01% | 2211 |
|
|
2025
Q2 | $19.7M | Sell |
60,300
-23,200
| -28% | -$6.42M | ﹤0.01% | 2155 |
|
|
2025
Q1 | $22.5M | Sell |
83,500
-19,800
| -19% | -$5.09M | ﹤0.01% | 1912 |
|
|
2024
Q4 | $24.3M | Sell |
103,300
-50,300
| -33% | -$13.2M | ﹤0.01% | 1958 |
|
|
2024
Q3 | $42.2M | Sell |
153,600
-101,700
| -40% | -$26.5M | 0.01% | 1372 |
|
|
2024
Q2 | $62M | Sell |
255,300
-1,700
| -0.7% | -$268K | 0.01% | 983 |
|
|
2024
Q1 | $38.4M | Buy |
257,000
+110,400
| +75% | +$18.4M | 0.01% | 1425 |
|
|
2023
Q4 | $28.1M | Buy |
146,600
+37,100
| +34% | +$6.32M | 0.01% | 1690 |
|
|
2023
Q3 | $19.4M | Buy |
109,500
+16,600
| +18% | +$3.17M | ﹤0.01% | 1896 |
|
|
2023
Q2 | $17.6M | Sell |
92,900
-18,500
| -17% | -$3.67M | ﹤0.01% | 2018 |
|
|
2023
Q1 | $22.3M | Sell |
111,400
-59,600
| -35% | -$12.5M | ﹤0.01% | 1812 |
|
|
2022
Q4 | $40.6M | Sell |
171,000
-8,600
| -5% | -$1.83M | 0.01% | 1291 |
|
|
2022
Q3 | $35.9M | Sell |
179,600
-179,100
| -50% | -$34.2M | 0.01% | 1326 |
|
|
2022
Q2 | $52.3M | Buy |
358,700
+270,200
| +305% | +$38.3M | 0.01% | 983 |
|
|
2022
Q1 | $14.5M | Sell |
88,500
-7,000
| -7% | -$1.07M | ﹤0.01% | 2415 |
|
|
2021
Q4 | $16.2M | Buy |
95,500
+28,700
| +43% | +$5.33M | ﹤0.01% | 2303 |
|
|
2021
Q3 | $12.6M | Sell |
66,800
-8,700
| -12% | -$1.63M | ﹤0.01% | 2676 |
|
|
2021
Q2 | $12.8M | Buy |
75,500
+26,600
| +54% | +$3.9M | ﹤0.01% | 2707 |
|
|
2021
Q1 | $6.9M | Buy |
48,900
+3,800
| +8% | +$572K | ﹤0.01% | 3612 |
|
|
2020
Q4 | $5.86M | Sell |
45,100
-25,600
| -36% | -$3.42M | ﹤0.01% | 3418 |
|
|
2020
Q3 | $10.3M | Sell |
70,700
-3,600
| -5% | -$512K | ﹤0.01% | 2263 |
|
|
2020
Q2 | $11M | Buy |
74,300
+14,900
| +25% | +$2.01M | ﹤0.01% | 2107 |
|
|
2020
Q1 | $6.47M | Sell |
59,400
-48,100
| -45% | -$5.55M | ﹤0.01% | 2395 |
|
|
2019
Q4 | $12.4M | Sell |
107,500
-75,800
| -41% | -$7.56M | 0.01% | 1979 |
|
|
2019
Q3 | $14.7M | Buy |
183,300
+153,500
| +515% | +$12.1M | 0.01% | 1771 |
|
|
2019
Q2 | $2.16M | Sell |
29,800
-55,300
| -65% | -$4.24M | ﹤0.01% | 4389 |
|
|
2019
Q1 | $7.95M | Sell |
85,100
-17,700
| -17% | -$1.48M | ﹤0.01% | 2351 |
|
|
2018
Q4 | $7.5M | Sell |
102,800
-69,900
| -40% | -$5.38M | ﹤0.01% | 2240 |
|
|
2018
Q3 | $15.1M | Buy |
172,700
+83,100
| +93% | +$8.36M | 0.01% | 1656 |
|
|
2018
Q2 | $8.82M | Buy |
89,600
+36,900
| +70% | +$3.66M | ﹤0.01% | 2073 |
|
|
2018
Q1 | $6.28M | Buy |
52,700
+14,000
| +36% | +$1.8M | ﹤0.01% | 2204 |
|
|
2017
Q4 | $4.92M | Sell |
38,700
-84,600
| -69% | -$10.6M | ﹤0.01% | 2498 |
|
|
2017
Q3 | $14.5M | Buy |
123,300
+96,300
| +357% | +$8.22M | 0.01% | 1289 |
|
|
2017
Q2 | $2.15M | Buy |
27,000
+5,100
| +23% | +$326K | ﹤0.01% | 3084 |
|
|
2017
Q1 | $1.12M | Sell |
21,900
-3,700
| -14% | -$171K | ﹤0.01% | 3837 |
|
|
2016
Q4 | $958K | Sell |
25,600
-800
| -3% | -$33.5K | ﹤0.01% | 3914 |
|
|
2016
Q3 | $1.79M | Buy |
26,400
+10,300
| +64% | +$727K | ﹤0.01% | 3105 |
|
|
2016
Q2 | $893K | Sell |
16,100
-10,700
| -40% | -$674K | ﹤0.01% | 3700 |
|
|
2016
Q1 | $1.68M | Buy |
26,800
+16,300
| +155% | +$1.08M | ﹤0.01% | 2841 |
|
|
2015
Q4 | $988K | Sell |
10,500
-43,100
| -80% | -$4M | ﹤0.01% | 3588 |
|
|
2015
Q3 | $4.31M | Sell |
53,600
-10,900
| -17% | -$1.21M | ﹤0.01% | 2096 |
|
|
2015
Q2 | $7.73M | Buy |
64,500
+14,400
| +29% | +$1.72M | 0.01% | 1660 |
|
|
2015
Q1 | $5.23M | Buy |
50,100
+31,100
| +164% | +$3.15M | 0.01% | 1999 |
|
|
2014
Q4 | $1.84M | Sell |
19,000
-4,400
| -19% | -$408K | ﹤0.01% | 3010 |
|
|
2014
Q3 | $1.83M | Buy |
23,400
+11,300
| +93% | +$729K | ﹤0.01% | 2954 |
|
|
2014
Q2 | $764K | Sell |
12,100
-3,800
| -24% | -$226K | ﹤0.01% | 3840 |
|
|
2014
Q1 | $1.07M | Buy |
15,900
+500
| +3% | +$38.7K | ﹤0.01% | 3335 |
|
|
2013
Q4 | $991K | Sell |
15,400
-7,100
| -32% | -$424K | ﹤0.01% | 3232 |
|
|
2013
Q3 | $1.44M | Buy |
22,500
+9,700
| +76% | +$483K | ﹤0.01% | 2714 |
|
|
2013
Q2 | $397K | Buy |
+12,800
| New | +$341K | ﹤0.01% | 4064 |
|
Other funds holding ALNY
VPM
VCM
Citadel Advisors's ALNY Position: Q1 2026 in Review
Citadel Advisors reduced its Alnylam Pharmaceuticals (ALNY) stake by 39% in Q1 2026, selling an estimated $5.12M and leaving 23,415 shares worth $7.75M. The position accounts for ﹤0.01% of the portfolio, ranked #3628.
Citadel Advisors first reported a position in ALNY in Q2 2013 and has held it in 45 quarters since. The position peaked at $196M in Q2 2025. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Citadel Advisors held 23,415 shares of Alnylam Pharmaceuticals worth $7.75M as of Q1 2026.
- Citadel Advisors sold 15,044 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $5.12M.
- Alnylam Pharmaceuticals made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #3628 holding.
- Citadel Advisors first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 45 quarters since.
- Citadel Advisors's Alnylam Pharmaceuticals position peaked at $196M in Q2 2025.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.